Randomized Phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 22; no. 14_suppl; p. 5139
Main Authors Oskay-Özcelik, G., Sehouli, J., Sommer, H., Klare, P., Stauch, M., Zeimet, A., Paulenz, A., Renziehausen, K., Keil, E., Lichtenegger, W.
Format Journal Article
LanguageEnglish
Published 15.07.2004
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2004.22.14_suppl.5139